LCM
VRTX icon

Legato Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Legato Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$361K Sell
808
-333
-29% -$155K 0.03% 597
2025
Q4 		$517K Buy
+1,141
New +$492K 0.04% 534

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Legato Capital Management's VRTX Position: Q1 2026 in Review

Legato Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 29% in Q1 2026, selling an estimated $155K and leaving 808 shares worth $361K. The position accounts for 0.03% of the portfolio, ranked #597.

Legato Capital Management first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. The position peaked at $517K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Legato Capital Management held 808 shares of Vertex Pharmaceuticals worth $361K as of Q1 2026.
  • Legato Capital Management sold 333 Vertex Pharmaceuticals shares in Q1 2026, an estimated $155K.
  • Vertex Pharmaceuticals made up 0.03% of Legato Capital Management's portfolio in Q1 2026, its #597 holding.
  • Legato Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Legato Capital Management's Vertex Pharmaceuticals position peaked at $517K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.